UAE’s Healthcare to Drive Next Decade of Growth
Dubai science park’s business partners are expanding the dialogue and the possibilities of pharmaceutical, medical equipment, treatments and more. Creating a space where this community can meet, exchange experiences and propose new ideas for an impactful healthcare ecosystem that enhances the lives of UAE residents.
Abu Dhabi Life Science Mission to Strengthen Ties with the USA
Headed by HE Abdulla bin Mohammed Al Hamed, Chairman of the Department of Health – Abu Dhabi (DoH), a high-profile Abu Dhabi delegation will be visiting the United States of America this month,
The visit is expected to see meetings and groundbreaking agreement signing with leading partners to explore and activate collaboration in life sciences, digital health, research and development, supply chain and other areas. This visit seeks to bring innovative treatments and breakthrough solutions to the UAE and the MENA region.
Abu Dhabi Joins AstraZeneca’s A. Catalyst Network to Attract & Support Start-ups Globally
This partnership highlights DoH’s commitment to enhancing digital healthcare in the UAE and improving patient experience. The partnership will support embedding an entrepreneurial mindset in the UAE youth, building skills and capabilities to lead and spearhead the future of life sciences in Abu Dhabi and the world.
Etihad Cargo Signs MoU with B Medical Systems for Sustainable Pharmaceutical Solutions
Etihad Group, has entered into a memorandum of understanding with B Medical Systems to develop and launch an airline-specific passive temperature-controlled solution for the transportation of life-saving drugs, vaccines and high-value pharmaceuticals. Container units that utilize passive cooling technology to retain temperatures from -80 to 25c without requiring an external power source will be developed.
Marubeni Acquires Stakes in Lunatus, a Middle East Healthcare Turnkey Solutions Provider
Through the broad regional Lunatus network, Marubei will bridge the Japan-Middle East markets and will bring Japanese high-quality pharmaceuticals and medical devices to accommodate the increasing demand in the region, this transaction will enable Marubeni to expand its pharmaceutical and medical device business network from china to the Middle East and Africa.
MEA precision medicine market projected to expand by 9.96%, leading to a revenue of USD 2.51 Bn by 2023, Quadintel Reports
Because the use of IoMT and healthcare technologies has increased in recent years, the precision medicine market in the Middle East and Africa is likely to rise significantly. Pharmaceutical and biotech firms in the region are working to improve medicines and precision medical solutions. Diagnostic firms are using a variety of technologies to try to enhance the healthcare industry. Precision medicine market expansion in the area is being aided by the implementation of technologies such as next-generation sequencing and gene therapy.
SQZ Biotechnologies Announces Generation of Dopaminergic Neurons from Human Pluripotent Stem Cells
Through single-step delivery of 6 cell-fate encoding RNAs. Use of non-viral, self-amplifying RNA enhanced and lengthened transcription factors expression, driving the signaling required for dopamine-producing neuron development
Sensorion to Present at the Gene Therapy Development and Manufacturing Conference in June 2022
Sensorion is a pioneering clinical-stage biotech company, which specializes in the development of novel therapies to restore, treat and prevent hearing loss disorders. Sensorion has entered into a broad strategic collaboration with Institut Pasteur focused on the genetics of hearing. It has two gene therapy programs aimed at correcting hereditary monogenic forms of deafness including deafness caused by a mutation of the gene encoding for Otoferlin, and hearing loss related to mutation in GJB2 gene to potentially address important hearing loss segments in adults and children. The Company is also working on the identification of biomarkers to improve diagnosis of these underserved illnesses.
BIO Returns to San Diego with Innovation and Partnering on the Menu
Biotechnology Innovation Organization annual conference has returned to San Diego convention center, bringing thousands of life sciences companies from across the globe to the annual in-person networking event, the discussions will cover Covid-19, the future of mRNA-based programs, rare genetic diseases, cancer, immunoinflammatory conditions and even cardiovascular diseases.
Ambys Medicines to Present Data from Universal Human Hepatocyte Program at the 2022 ISSCR Annual Meeting
Ambys, a company pioneering cell-replacement therapies for patients with liver disease using a range of gene editing and delivery technologies, announced that data from its universal hepatocyte program will be presented at the 2022 International Society for Stem Cell Research (ISSCR) Annual Meeting, which is scheduled for June 2022 in San Francisco and virtually. Ambys will present proof-of-concept data on its genetically engineered hypoimmunogenic human hepatocytes during an oral session.
About Author
